Datasets:

---

Recag

/

Rp_CommonC_481

like 0

ERROR: type should be string, got "https://www.barrons.com/articles/holiday-travel-season-is-starting-will-thanksgiving-be-the-next-superspreader-event-51606137074\nThe Barron's Daily\nHoliday Travel Season Is Starting. Will Thanksgiving Be the Next Superspreader Event?\nUpdated Nov. 23, 2020 12:58 pm ET / Original Nov. 23, 2020 8:11 am ET\nTravelers retrieve their luggage at Newark International Airport in New Jersey on Nov. 21.\nKENA BETANCUR/AFP via Getty Images\nIt’s the start of the holiday travel season—and this one promises to be like no other.\nMore than 1 million people flew home for the Thanksgiving holiday this past Friday. That’s only the second time 1 million passengers have flown since March 16. U.S. commercial air travel jumped about 27% on Friday and Saturday combined compared with a week ago.\nThat’s close to the holiday spike U.S. travelers are familiar with, just off a smaller base. Before the pandemic, about 2.4 million passengers flew commercially in the U.S. each day, and that number goes up by about one-third in the days surrounding Thanksgiving.\nA morning briefing on what you need to know in the day ahead, including exclusive commentary from Barron's and MarketWatch writers.\nAmericans will be driving too. The American Automobile Association forecasts 50 million Americans will travel for the Thanksgiving holiday. That’s down about 7% compared with 2019, but AAA notes many travelers are taking a wait-and-see approach this year.\nWhich is as it should be. More than 520,000 new coronavirus infections were reported over the weekend, up almost 9% from the prior week, and the CDC is urging Americans to host smaller, shorter Thanksgiving gatherings.\nIn the coming weeks, U.S. citizens, and investors, will find out how Americans did at slowing the spread—or whether Thanksgiving became a superspreading event.\n—Al Root\n*** Join Barron’s senior managing editor Lauren R. Rublin, deputy editor Ben Levisohn and a special guest to discuss the outlook for financial markets, industry sectors, and individual stocks today at noon. Register here.\nOxford University and AstraZeneca Announce Vaccine Efficacy of Up to 90%\nU.K.-based drugmaker AstraZeneca said Monday that the coronavirus vaccine it is developing with Oxford University had shown an average efficacy of 70% in the Phase 3 trials, and that it would “immediately prepare regulatory submission” of the data for approval by regulatory authorities around the world, for conditional or early approval.\nThe vaccine injected at half a dose followed by a full dose at least one month later showed efficacy of 90%, whereas a full dose followed by another full dose within the same time frame showed only a 62% efficacy, the company said in a release.\nU.S. and European health authorities usually demand a 50% efficacy before green lighting a vaccine.\n“We have an effective vaccine that will save many lives,” said Andrew Pollard, the chief investigator of the trial at Oxford University.\nA vaccine developed by U.S. pharma group Pfizer and German BioNtech, and another one by U.S. biotech Moderna, have shown efficacy of more than 95% in late stage trials, according to the companies.\nWhat’s Next: The news adds to the string of positive medical news coming from research labs and drug companies in past weeks, and will brighten the Christmas season for households and businesses. But it will take months before populations can be vaccinated on a scale that will start curbing the pandemic.\nHere’s When the First Americans Could Get a Coronavirus Vaccine\nThe first Covid-19 vaccines could be administered as soon as Dec. 12, Dr. Moncef Slaoui, the chief science advisor to the Trump administration’s “Operation Warp Speed,” said.\nIf the Food and Drug Administration gives Pfizer’s vaccine an emergency-use authorization when its vaccine advisory committee meets Dec. 10, “hopefully, people will start to be immunized, I would say, within 48 hours from the approval,” Dr. Slaoui told ABC “This Week.”\nLike Pfizer, Moderna is also expected to file for an emergency-use authorization for its vaccine, which could be approved as early as Dec. 17, when the FDA committee reviews it. He noted that the Centers and Disease Control and Prevention and Advisory Committee on Immunization Practices will also review the data.\nWhen asked on CNN when life might return to normal, Dr. Slaoui estimated by mid-May 2021 if 70% of the population takes a 95% effective vaccine by then. Some 20 million people could be vaccinated in December and another 30 million in January, assuming the FDA approves the drugs.\nAstraZeneca said Monday it would immediately prepare regulatory submission of its promising data and will seek emergency-use authorization from the World Health Organization. Pending regulatory review, the company said it expects to have hundreds of millions of doses globally available on approval.\nRegeneron’s antibody cocktail, which Trump received, became the second antibody treatment to receive emergency-use authorization, following Eli Lilly’ s antibody treatment earlier this month. Both appear to work best when given early in the course of the disease and neither are authorized for hospitalized patients or those receiving oxygen.\nWhat’s Next: Dr. Slaoui told ABC he hasn’t had contact with the Biden transition team, adding on NBC that he has been informed not to share confidential information with anyone outside the current administration. Biden’s transition team has warned a lack of communication could lead to additional, unnecessary deaths.\nBiden Set to Fill Cabinet This Week as More States Certify Results\nPresident-elect Joe Biden is expected to nominate former State Department official Antony Blinken as his secretary of state, according to multiple reports. Veteran diplomats and Obama administration alumni Linda Thomas-Greenfield and Jake Sullivan are expected to be nominated to the respective roles of United Nations ambassador and national security adviser.\nBlinken served as national security adviser to Biden from 2009-2013. Sullivan succeeded Blinken as the Obama administration’s adviser in 2013, playing a role in negotiations that led to the Iran nuclear deal. Thomas-Greenfield was assistant secretary of state for African affairs from 2013-2017. She is Biden’s first Black nominee.\nThe three appointments confirm that Biden’s foreign policy will mark a return to the traditional fold of American diplomacy. Blinken is known as a defender of global alliances and international agreements, and has described Europe as “first resort, not last resort, when it comes to contending with the challenges” the U.S. faces.\nThose first cabinet picks will come Tuesday, Biden’s chief of staff Ron Klain told ABC. Last week, Biden said he would announce his Treasury Secretary nominee around Thanksgiving. Speculation has swirled that it could be former Federal Reserve Chief Janet Yellen, TIAA CEO Roger Ferguson, or Fed Governor Lael Brainard.\nMore states will certify election results this week. A federal judge rejected efforts to block certification of millions of voters in Pennsylvania, which, along with Michigan, is set to certify its election results Monday. Nevada certifies its results Tuesday. Georgia certified its results showing Biden won the state on Friday.\nWhat’s Next: Biden’s January 20 inauguration ceremony will feature “scaled down versions of the existing traditions,” due to the pandemic, Klain told ABC. “They’re going to try to have an inauguration that honors the importance and the symbolic meaning of the moment, but also does not result in the spread of disease.”\n—Connor Smith, Pierre Briançon\nBritain, France Prepare Cautious Christmas Easing of Pandemic Lockdowns\nBritish Prime Minister Boris Johnson and French President Emmanuel Macron will announce this week some easing of the one-month lockdowns due to expire in both countries at the end of November, to give businesses and families some relief around the Christmas season.\nAccording to the Times of London, Johnson is due to announce in Parliament Monday afternoon that nonessential shops as well as gyms will be allowed to reopen from Dec. 3 across England.\nJohnson’s “Covid-19 winter plan” will mark a return to a three-tier system of restrictions similar to what was in force before the current lockdown, with restrictions increasing in some towns or regions depending on the level of infections.\nMacron is expected to announce Tuesday in a televised speech the easing of restrictions, including the reopening of nonessential shops, but restaurants and bars should remain closed, according to Le Monde.\n“Nothing is worse than uncertainty and the impression of non-ending gloom,” the French president said in a newspaper interview Sunday.\nWhat’s Next: Government leaders seem to have learned the lesson of their early-summer mistakes, when the quick end of lockdowns triggered a virus second wave whose strength took them by surprise. All are warning that some form of restrictions will have to remain for a few months more.\nWhy International Stocks Should Be on Your Radar\nBarron’s spoke with three international money managers and an economist for insights about the outlook for international stocks amid a recovery. Here are some key takeaways:\nInvestors focused just on FAANG stocks are missing out on innovation and fast-growing companies poised to prosper on the global stage. The global economic recovery over the next year “will favor more cyclically oriented or value companies and those geared into global trade,” Eaton Vance’s Chris Dyer says.\nBaillie Gifford’s Jenny Davis points to new billion-dollar tech companies in Europe, Hong Kong, and China. “We’ve seen massive growth in listed stocks there,” she says. “Not only that—these are really inefficient markets. Now is the time to be going international.”\nAs a coronavirus resurgence hits many Western countries, “the ability of many Asian countries to contain it has put them on the path to near-normalcy. China and its neighbors stand out, especially amid deterioration in the U.S. and Europe,” says Torsten Sløk, chief economist at Apollo Global Management.\nWhat’s Next: For our panel’s picks of 20 international stocks investors should consider, check out the full list on Barron’s.\nMarketWatch Wants to Hear From You\nThe Trump administration is reportedly looking to end the conservatorship of Fannie Mae and Freddie Mac. What would this mean for home buyers?\nA MarketWatch correspondent will answer this question soon. In the meantime, send any questions you would like answered to thebarronsdaily@barrons.com.\nCorrections & amplifications: Eli Lilly’s Covid-19 treatment is a single antibody therapy. A previous version of this article incorrectly said it was a cocktail of antibodies.\nRoger Ferguson is CEO of TIAA until March 31, 2021. A previous version of this article incorrectly said he was the former CEO.\n—Newsletter edited by Anita Hamilton, Stacy Ozol, Ben Levisohn, and Matt Bemer"